Literature DB >> 20113973

Biomarkers for tuberculosis disease activity, cure, and relapse.

Patrick Peter John Phillips, Geraint R Davies, Denis A Mitchison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20113973     DOI： 10.1016/S1473-3099(09)70256-7

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  12 in total

1.  Comparative proteomic analysis of serum diagnosis patterns of sputum smear-positive pulmonary tuberculosis based on magnetic bead separation and mass spectrometry analysis.

Authors:  Jiyan Liu; Tingting Jiang; Feng Jiang; Dandan Xu; Liliang Wei; Chong Wang; Zhongliang Chen; Xing Zhang; Jicheng Li
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Tuberculosis drug development: ensuring people living with HIV are not left behind.

Authors:  Anne F Luetkemeyer; Haileyesus Getahun; Gabriel Chamie; Christian Lienhardt; Diane V Havlir
Journal:  Am J Respir Crit Care Med       Date:  2011-08-25       Impact factor: 21.405

3.  Monitoring Therapeutic Response in a Case of Extrapulmonary Tuberculosis by Serial F-18 FDG PET/CT.

Authors:  Yong Hyun Park; Chang Min Yu; Eun Sil Kim; Jun Oh Jung; Han Seok Seo; Ju Hyoung Lee; So Chong Hur; So Yeon Kim; Hyon Young Lee
Journal:  Nucl Med Mol Imaging       Date:  2011-11-10

4.  Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.

Authors:  Erlina Burhan; Carolien Ruesen; Rovina Ruslami; Arum Ginanjar; Hadiarto Mangunnegoro; Purwantyastuti Ascobat; Rogier Donders; Reinout van Crevel; Rob Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

Review 5.  Assessment of treatment response in tuberculosis.

Authors:  Neesha Rockwood; Elsa du Bruyn; Thomas Morris; Robert J Wilkinson
Journal:  Expert Rev Respir Med       Date:  2016-03-31       Impact factor: 3.772

6.  Soluble markers of the Toll-like receptor 4 pathway differentiate between active and latent tuberculosis and are associated with treatment responses.

Authors:  Siri L Feruglio; Marius Trøseid; Jan Kristian Damås; Dag Kvale; Anne Ma Dyrhol-Riise
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

7.  Screening and identification of six serum microRNAs as novel potential combination biomarkers for pulmonary tuberculosis diagnosis.

Authors:  Xing Zhang; Jing Guo; Shufeng Fan; Yanyuan Li; Liliang Wei; Xiuyun Yang; Tingting Jiang; Zhongliang Chen; Chong Wang; Jiyan Liu; Zepeng Ping; Dandan Xu; Jiaxiong Wang; Zhongjie Li; Yunqing Qiu; Ji-Cheng Li
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

8.  A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP).

Authors:  Patrick P J Phillips; Kelly E Dooley; Stephen H Gillespie; Norbert Heinrich; Jason E Stout; Payam Nahid; Andreas H Diacon; Rob E Aarnoutse; Gibson S Kibiki; Martin J Boeree; Michael Hoelscher
Journal:  BMC Med       Date:  2016-03-23       Impact factor: 8.775

9.  Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.

Authors:  Patrick P J Phillips; Carl M Mendel; Divan A Burger; Angela M Crook; Angela Crook; Andrew J Nunn; Rodney Dawson; Andreas H Diacon; Stephen H Gillespie
Journal:  BMC Med       Date:  2016-02-04       Impact factor: 8.775

10.  Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis.

Authors:  Lingshuang Lv; Tiecheng Li; Kun Xu; Peiyi Shi; Biyu He; Weimin Kong; Jianming Wang; Jian Sun
Journal:  Infect Drug Resist       Date:  2018-01-23       Impact factor: 4.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.